

**REMARKS**

Reconsideration of this application is requested. Claims 20-43 are in the case.

**I. PRIORITY**

The Examiner has asserted that the Applicants have not provided an English language translation of the Swedish foreign priority patent applications. In light of this, the priority date has not been perfected. Reconsideration of this position is respectfully requested.

The Swedish priority patent applications for this application were filed in the English language. Certified copies were submitted during the international phase of the PCT International Application PCT/SE00/00756. Applicants have therefore complied with all of the requirements to perfect the priority claim in this application. An indication to that effect is requested in the next paper to issue in this application.

**II. ABSTRACT**

A new abstract is presented on a separate sheet attached to this response. The abstract is believed to be in compliance with the formal requirements.

**III. THE 35 U.S.C. § 101 REJECTION**

Claim 19 stands rejected under 35 U.S.C. § 101 as being in "use" format. Without conceding to the merit of this rejection, claim 19 has been canceled without prejudice. Reconsideration and withdrawal of the 35 U.S.C. § 101 rejection are accordingly respectfully requested.

**IV. THE 35 U.S.C. § 112, SECOND PARAGRAPH, REJECTION**

Claims 3, 4, 9 and 18 stand rejected under 35 U.S.C. § 112, second paragraph, for the reasons detailed on pages 2 and 3 of the Action. In response, all of the claims in this application have been canceled without prejudice and replaced by the new claims presented herewith.

The Examiner's points have received attention in the preparation of the new claims. The following comments are offered.

Claims 3, 4 and 18 stand rejected as allegedly indefinite in view of the use of the term "and/or". In response, in the new claims presented herewith, the term "and/or" does not appear.

Claim 9 has been rejected as allegedly indefinite in view of its dependency. In response, the new claims presented herewith are in proper dependent form.

Claim 19 stands rejected as directed to a "use". As noted earlier, claim 19 has been canceled without prejudice.

Withdrawal of the outstanding formal rejection is now believed to be in order. Such action is respectfully requested.

**V. ALLOWABLE SUBJECT MATTER**

It is noted, with appreciation, claim claims 1, 2, 5-8 and 10-17 are free of the prior art and allowable. The amendments presented herewith, it is believed that all of the claims in this application are now in allowable condition. Early notice to that effect is respectfully requested.

**GUSTAFSSON, David**  
Serial No. **09/582,863**


Allowance is awaited.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE ABSTRACT**

A new Abstract is presented on a separate sheet attached to this Response.

**IN THE CLAIMS**

Please cancel claims 1-19 without prejudice.

Please add new claims 20-43 as presented herewith.

---

**ABSTRACT OF THE DISCLOSURE**

Q2 A kit of parts containing (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, and (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other. The kit is useful in the treatment of conditions in which inhibition of thrombin is required or desired.

---